Compare Mongodb Inc (MDB) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs Novo Nordisk A/S — how do they compare? Mongodb Inc trades at $372.42 (market cap $29.24B), while Novo Nordisk A/S trades at $38.12 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 5.7× Mongodb Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Mongodb Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mongodb Inc for 45 Days and Novo Nordisk A/S for 116 Days on average.
| MDB | NVO | |
|---|---|---|
Market Cap | $29.24B | $165.31B |
Volume | 1,304,995 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $472.29 | $63.98 |
52-Week Low | $225.95 | $35.29 |
Typical Hold Time | 45 Days | 116 Days |
Enterprise Value | $26.86B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MongoDB (MDB) trades at $363.03, up 0.64% today, with a bearish technical signal despite recent positive earnings beats. The company reported strong revenue growth, reaching $2.01 billion in 2025, but remains unprofitable with a net loss of $129.07 million. Recent news highlights AI product launches and a CEO transition, with analysts maintaining a bullish consensus price target of $456.76.
The outlook is mixed: strong revenue growth and AI initiatives offer upside, but high valuation ratios and persistent losses pose risks. Investor sentiment is cautiously optimistic, though technical indicators suggest near-term pressure. Key risks include execution challenges and competitive threats in the database market.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
